DR info

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

Drugs and their primary sponsors and trial info

3 MPDN pulse + PDN + CSA
   Istituto Giannina Gaslini
      2006   Phase 3   NCT00323960   Italy;
3 MPDN pulse + PDN + MTX
   Istituto Giannina Gaslini
      2006   Phase 3   NCT00323960   Italy;
44/154/85-C
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
44/196/81-C
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
56/104/75-C
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-FR   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-ES   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-DE   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
Abatacept
   Bristol-Myers Squibb K.K.
      2017   Phase 3   JPRN-JapicCTI-173670   Japan, Asia except Japan, North America, South America, Europe, Oceania;
   George Washington University
      2015   Phase 4   NCT02594735   United States;
   Karolinska University Hospital
      2012   -   EUCTR2009-015957-20-GB   Sweden;United Kingdom;
   Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2020   Phase 0   ChiCTR2000036282   China;
   The First Affiliated Hospital with Nanjing Medical University
      2021   Early Phase 1   NCT04946669   China;
Abatacept Active Treatment
   Karolinska Institutet
      2011   Phase 2   NCT01315938   Czech Republic;Czechia;Sweden;
Abatacept Delayed-Onset Treatment
   Karolinska Institutet
      2011   Phase 2   NCT01315938   Czech Republic;Czechia;Sweden;
Abatacept subcutaneous
   Bristol-Myers Squibb
      2017   Phase 3   NCT02971683   Australia;Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States;
Acthar
   Phoenix Neurological Associates, LTD
      2013   -   NCT01637064   United States;
Adrenocorticotropic Hormone Gel
   Rohit Aggarwal, MD
      2013   Phase 2   NCT01906372   United States;
Alendronate versus alfacalcidol (1-alpha OH vitamin D)
   UMC Utrecht
      2000   Phase 3   NCT00138983   Netherlands;
Alfacalcidol 2 micrograms/ml
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom;
Anakinra
   Karolinska Institutet
      2003   Phase 2/Phase 3   NCT01165008   Sweden;
Anti-Beta Interferon (PF-06823859)
   Pfizer
      2021   Phase 2   NCT05192200   United States;
Anti-pandemic H1N1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Apremilast
   Okiyama Naoko
      2020   Phase 1-2   JPRN-jRCTs031200005   Japan;
   Stanford University
      2010   -   NCT01140503   United States;
   Tulane University
      2018   Phase 2   NCT03529955   United States;
BAF312
   Novartis Pharma Services AG
      2009   -   EUCTR2008-006311-21-SE   Czech Republic;Hungary;Sweden;United Kingdom;
      2009   -   EUCTR2008-006311-21-HU   Czech Republic;Hungary;Sweden;United Kingdom;
   Novartis Pharmaceuticals
      2013   Phase 2   NCT02029274   Belgium;Canada;China;Czech Republic;Czechia;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States;
      2013   Phase 2   NCT01801917   Belgium;Canada;Czech Republic;Czechia;Hungary;Netherlands;Poland;Switzerland;Taiwan;United States;
      2010   Phase 2   NCT01148810   Czech Republic;Czechia;Hungary;Poland;Sweden;United Kingdom;United States;
BAF312 0,5 mg tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
BAF312 0.25 mg tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom;
BAF312 0.25mg tablet
   Novartis Pharma Services AG
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom;
BAF312 1 mg tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom;
BAF312 1mg tablet
   Novartis Pharma Services AG
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom;
BAF312 2 mg tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
BAF312 4mg tablet
   Novartis Pharma Services AG
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom;
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom;
BAF312 5 mg tablet
   Novartis Pharma Services AG
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom;
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom;
BAF312 hemifumarate
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-001799-39-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Japan;Poland;Taiwan;United States;
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
      2014   -   EUCTR2013-001799-39-PL   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States;
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States;
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States;
BAF312X
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States;
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
Baricitinib
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT04972760   France;
   Eli Lilly and Company
      2007   -   NCT01724580   United Kingdom;United States;
Basiliximab
   RenJi Hospital
      2017   Phase 2   NCT03192657   China;
Begelomab
   ADIENNE SA
      2021   Phase 2   EUCTR2021-000898-83-IT   Italy;
CD7 CAR T-cells
   Zhejiang University
      2022   Early Phase 1   NCT05239702   China;
Calcineurin Inhibitors
   RenJi Hospital
      2017   Phase 2   NCT03192657   China;
Cervarix suspensie voor injectie
   University Medical Center Utrecht
      2009   -   EUCTR2008-008169-36-NL   Netherlands;
Ciclosporin
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   Istituto Giannina Gaslini
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Creapure
   The Hospital for Sick Children
      2015   -   NCT02267005   Canada;
Creatine
   University of Sao Paulo
      2011   -   NCT01217320   Brazil;
CsA
   Guangdong Provincial People's Hospital
      2019   Phase 4   ChiCTR1900025087   China;
CyA
   Department of Neurology and Rheumatology, Shinshu University School of Medicine
      2009   -   JPRN-UMIN000001866   Japan;
Cyclophosphamide
   Department of Rheumatology and Immunology, Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR1900028143   China;
   Kyushu University
      2010   Phase 2   JPRN-UMIN000031931   Japan;
   Zhongshan Hospital of Fudan University
      2020   -   ChiCTR2000036709   China;
Cyclophosphamide Injection 1g
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
Cyclosporin
   Zhongshan Hospital of Fudan University
      2020   -   ChiCTR2000036709   China;
Cyclosporine
   Istituto Giannina Gaslini
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom;
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan;
Cyclosporine A
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   University Hospital Gent
      2006   -   EUCTR2005-003956-37-BE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Denosumab
   Indiana University
      2019   Phase 1/Phase 2   NCT02418273   United States;
EMEA/H/C/000701
   Karolinska University Hospital
      2012   -   EUCTR2009-015957-20-GB   Sweden;United Kingdom;
Etanercept
   Brigham and Women's Hospital
      2006   Phase 1   NCT00112385   United States;
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2/Phase 3   NCT00035958   United States;
Fractionated Carbon Dioxide (FCO2) Laser
   Alison Ehrlich
      2012   Phase 2   NCT01572844   United States;
GB-0998
   Japan Blood Products Organization
      2006   Phase 3   NCT00335985   Japan;
Gamma Globulin
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001261   United States;
Gevokizumab
   Institut de Recherches Internationales Servier (IRIS)
      2014   -   EUCTR2012-005772-34-GR   Australia;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2014   -   EUCTR2012-005772-34-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2012-005772-34-IT   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2012-005772-34-CZ   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-SE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-HU   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-DE   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Laboratorios Servier S.L
      2013   -   EUCTR2012-005772-34-ES   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
   Servier Research and Development Ltd.
      2014   Phase 2   EUCTR2012-005772-34-GB   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Glucose Tablet
   The Hospital for Sick Children
      2015   -   NCT02267005   Canada;
Gold
   Department of Dermatology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University
      2016   -   ChiCTR-DDD-16009687   China;
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2020   Phase 0   ChiCTR2000031286   China;
Grapefruit
   Department of Rheumatology and Clinical Immunology, Kyoto University Hospital
      2014   -   JPRN-UMIN000013546   Japan;
H.P. Acthar Gel
   The Cleveland Clinic
      2015   Phase 4   NCT02245841   United States;
H5G1.1-mAb
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2000   Phase 2   NCT00005571   United States;
Hizentra
   CSL BEHRING GMBH
      2019   Phase 3   EUCTR2018-003171-35-IT   Argentina;Australia;Canada;European Union;France;Germany;Italy;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   CSL Behring LLC
      2020   Phase 3   EUCTR2018-003171-35-DE   Argentina;Australia;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003171-35-FR   Argentina;Australia;Canada;European Union;France;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003171-35-ES   Argentina;Australia;Canada;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
Human immunoglobulin G
   CSL BEHRING GMBH
      2019   Phase 3   EUCTR2018-003171-35-IT   Argentina;Australia;Canada;European Union;France;Germany;Italy;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   CSL Behring
      2019   Phase 3   NCT04044690   Australia;Belgium;France;Germany;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   CSL Behring LLC
      2020   Phase 3   EUCTR2018-003171-35-DE   Argentina;Australia;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003171-35-FR   Argentina;Australia;Canada;European Union;France;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003171-35-ES   Argentina;Australia;Canada;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
Human normal immunoglobulin (IVIg)
   Orfagen
      2006   -   EUCTR2005-002463-88-DE   Austria;Czech Republic;Germany;Hungary;Italy;
      2006   -   EUCTR2005-002463-88-AT   Austria;Czech Republic;Germany;Hungary;Italy;
Human normal immunoglogulin (IVIg)
   Orfagen
      2009   -   EUCTR2005-002463-88-CZ   Austria;Czech Republic;Germany;Hungary;Italy;
Humanised IgG1K monoclonal antibody against interferon beta
   PFIZER INC
      2021   Phase 2   EUCTR2020-004228-41-IT   Germany;Hungary;Italy;Poland;Spain;United States;
   Pfizer Inc.
      2022   Phase 2   EUCTR2021-004787-10-PL   Australia;Germany;Hungary;Italy;Poland;Spain;United States;
      2022   Phase 2   EUCTR2021-004787-10-HU   Australia;Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-PL   Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-HU   Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-ES   Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-DE   Germany;Hungary;Italy;Poland;Spain;United States;
IFN-K
   Neovacs SA
      2016   Phase 2   EUCTR2016-000137-52-DE   France;Germany;Italy;Switzerland;United Kingdom;
IFN-Kinoid
   Neovacs
      2017   Phase 2   NCT02980198   France;Germany;Italy;Switzerland;United Kingdom;
IFN-Kinoid Drug Substance
   Neovacs SA
      2016   Phase 2   EUCTR2016-000137-52-DE   France;Germany;Italy;Switzerland;United Kingdom;
IFNa-Kinoid
   Neovacs SA
      2016   Phase 2   EUCTR2016-000137-52-DE   France;Germany;Italy;Switzerland;United Kingdom;
IGVENA*FL 200ML 10G+SET
   ORFAGEN
      2006   -   EUCTR2005-002463-88-IT   Austria;Czech Republic;Germany;Hungary;Italy;
IMMUNOGLOBULIN G
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2018   Phase 3   EUCTR2016-002902-37-NL   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
      2017   Phase 3   EUCTR2016-002902-37-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;United States;
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
      2016   Phase 3   EUCTR2016-002902-37-CZ   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
IMO-8400
   Idera Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2015-003277-15-SE   Czech Republic;Hungary;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003277-15-HU   Czech Republic;Hungary;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003277-15-GB   Czech Republic;Hungary;Sweden;United Kingdom;United States;
IMO-8400 Dose Group 1
   Idera Pharmaceuticals, Inc.
      2015   Phase 2   NCT02612857   Hungary;United Kingdom;United States;
IMO-8400 Dose Group 2
   Idera Pharmaceuticals, Inc.
      2015   Phase 2   NCT02612857   Hungary;United Kingdom;United States;
Ig VENA (10g/200mL)
   Orfagen
      2010   -   EUCTR2005-002463-88-HU   Austria;Czech Republic;Germany;Hungary;Italy;
      2009   -   EUCTR2005-002463-88-CZ   Austria;Czech Republic;Germany;Hungary;Italy;
      2006   -   EUCTR2005-002463-88-DE   Austria;Czech Republic;Germany;Hungary;Italy;
      2006   -   EUCTR2005-002463-88-AT   Austria;Czech Republic;Germany;Hungary;Italy;
IgPro20
   CSL BEHRING GMBH
      2019   Phase 3   EUCTR2018-003171-35-IT   Argentina;Australia;Canada;European Union;France;Germany;Italy;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   CSL Behring LLC
      2020   Phase 3   EUCTR2018-003171-35-DE   Argentina;Australia;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003171-35-FR   Argentina;Australia;Canada;European Union;France;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003171-35-ES   Argentina;Australia;Canada;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
Immunoglobulin (Hizentra)
   Thomas Jefferson University
      2014   Early Phase 1   NCT02271165   United States;
Immunosuppressive Agents
   Karolinska University Hospital
      2010   -   NCT01813617   Sweden;
Impact
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China;
Infliximab
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 2   NCT00033891   United States;
Influvac
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands;
Isotone Kochsalz-Lösung 0, Braun Infusionslösung
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
JAK Inhibitor
   First Affiliated Hospital Xi'an Jiaotong University
      2020   Phase 4   NCT04966884   China;
JBT-101
   CORBUS PHARMACEUTICALS, INC
      2019   Phase 3   EUCTR2018-003273-10-IT   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2015   Phase 2   NCT02466243   United States;
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-SE   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-DE   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-BG   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
KZR-616
   Kezar Life Sciences, Inc.
      2020   Phase 2   NCT04628936   United States;
      2020   Phase 2   NCT04033926   Czechia;Germany;Poland;United States;
KZR-616 maleate
   Kezar Life Sciences, Inc.
      2021   Phase 2   EUCTR2019-002605-22-DE   Czech Republic;Czechia;Germany;Poland;United States;
      2020   Phase 2   EUCTR2019-002605-22-CZ   Czech Republic;Czechia;Germany;Hungary;Poland;United States;
L0133
   Orfagen
      2010   -   EUCTR2005-002463-88-HU   Austria;Czech Republic;Germany;Hungary;Italy;
      2009   -   EUCTR2005-002463-88-CZ   Austria;Czech Republic;Germany;Hungary;Italy;
      2006   -   EUCTR2005-002463-88-DE   Austria;Czech Republic;Germany;Hungary;Italy;
      2006   -   EUCTR2005-002463-88-AT   Austria;Czech Republic;Germany;Hungary;Italy;
LY3009104
   Eli Lilly and Company
      -   Phase 2   EUCTR2015-003424-31-GB   France;United Kingdom;United States;
Lenabasum
   CORBUS PHARMACEUTICALS, INC
      2019   Phase 3   EUCTR2018-003273-10-IT   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   NCT03813160   Bulgaria;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-SE   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-DE   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-BG   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Lipid-lowering agents (Artovastatin)
   University of Sao Paulo
      2017   -   NCT03092154   Brazil;
MEDI-545
   MedImmune LLC
      2008   Phase 1   NCT00533091   United States;
MEDI7734
   Viela Bio
      2016   Phase 1   NCT02780674   United States;
MMF
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China;
MTX
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China;
MabThera
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
Methimazole
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1995   Phase 2   NCT00001421   United States;
Methotrexat Lachema 2,5mg tbl.
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
Methotrexat Lachema 5 inj. sol
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
Methotrexate
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2/Phase 3   NCT00035958   United States;
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   Institute of Rheumatology, Prague
      2008   Phase 3   NCT00651040   Czech Republic;
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   University Hospital Gent
      2006   -   EUCTR2005-003956-37-BE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Methotrexate Lachema 5inj. sol
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
Methotrexate Wyeth 2,5mg tbl.
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden;
Methylprednisolone
   Department of Neurology and Rheumatology, Shinshu University School of Medicine
      2009   -   JPRN-UMIN000001866   Japan;
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China;
   Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032022   Japan;
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   Northwestern University
      1997   Phase 2   NCT00004357   United States;
   Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032193   Japan;
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan;
Methylprednisolone sodium succinate
   University Hospital Gent
      2006   -   EUCTR2005-003956-37-BE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Methylprednisoloni natrii succinas
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
Metoject 10 mg/ml
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden;
Metotrexat
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden;
Metotrexate
   Istituto Giannina Gaslini
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom;
NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
Nimenrix
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
Octagam
   Octapharma
      2017   Phase 3   NCT02728752   Canada;Czech Republic;Czechia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2018   Phase 3   EUCTR2016-002902-37-NL   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
      2017   Phase 3   EUCTR2016-002902-37-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;United States;
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
      2016   Phase 3   EUCTR2016-002902-37-CZ   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;
Octanorm
   Octapharma
      2018   Phase 3   NCT03686969   Czechia;Germany;Hungary;Poland;Romania;Russian Federation;
   Octapharma Pharmazeutika Produktionsges.m.b.H
      2018   Phase 3   EUCTR2017-002710-31-HU   Canada;Czech Republic;Germany;Hungary;Russian Federation;United States;
      2018   Phase 3   EUCTR2017-002710-31-DE   Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;United States;
      2018   Phase 3   EUCTR2017-002710-31-CZ   Canada;Czech Republic;Germany;Hungary;Russian Federation;United States;
One Alpha Drops
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom;
One-Alpha drops
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom;
Orencia
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2018   Phase 3   EUCTR2016-002269-77-IT   Australia;Brazil;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Mexico;Sweden;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-002269-77-SE   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States;
      2017   Phase 3   EUCTR2016-002269-77-FR   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States;
      2017   Phase 3   EUCTR2016-002269-77-DE   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States;
      2017   Phase 3   EUCTR2016-002269-77-CZ   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States;
Orencia (trade name)
   Karolinska University Hospital
      2012   -   EUCTR2009-015957-20-GB   Sweden;United Kingdom;
PF-06823859
   PFIZER INC
      2021   Phase 2   EUCTR2020-004228-41-IT   Germany;Hungary;Italy;Poland;Spain;United States;
   Pfizer Inc.
      2022   Phase 2   EUCTR2021-004787-10-PL   Australia;Germany;Hungary;Italy;Poland;Spain;United States;
      2022   Phase 2   EUCTR2021-004787-10-HU   Australia;Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-PL   Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-HU   Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-ES   Germany;Hungary;Italy;Poland;Spain;United States;
      2021   Phase 2   EUCTR2020-004228-41-DE   Germany;Hungary;Italy;Poland;Spain;United States;
PF-06823859 high
   Pfizer
      2018   Phase 2   NCT03181893   Australia;Germany;Hungary;Italy;Poland;Spain;United States;
PF-06823859 low
   Pfizer
      2018   Phase 2   NCT03181893   Australia;Germany;Hungary;Italy;Poland;Spain;United States;
PN-101
   Paean Biotechnology Inc.
      2021   Phase 1/Phase 2   NCT04976140   -
Pirfenidone
   Beijing Continent Pharmaceutical Co, Ltd.
      2018   Phase 3   NCT03857854   China;
   RenJi Hospital
      2016   Phase 4   NCT02821689   China;
   Renji Hospital, Shanghai Jiaotong University School of Medicine
      2014   -   ChiCTR-IPR-16007958   China;
Placebo
   Bristol-Myers Squibb K.K.
      2017   Phase 3   JPRN-JapicCTI-173670   Japan, Asia except Japan, North America, South America, Europe, Oceania;
Placebo IV
   Janssen Pharmaceutical K.K.
      2019   Phase 3   JPRN-JapicCTI-194822   Japan;
Placebo SC
   Janssen Pharmaceutical K.K.
      2019   Phase 3   JPRN-JapicCTI-194822   Japan;
Pneumovax 23
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands;
Prednisolon Pfizer
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden;
Prednisolone
   Department of Neurology and Rheumatology, Shinshu University School of Medicine
      2009   -   JPRN-UMIN000001866   Japan;
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China;
   Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032022   Japan;
   Northwestern University
      1997   Phase 2   NCT00004357   United States;
   Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032193   Japan;
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan;
   University Hospital Gent
      2006   -   EUCTR2005-003956-37-BE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Prednison 5, 20 Léciva por. tablet nob.
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden;
Prednisone
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2/Phase 3   NCT00035958   United States;
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China;
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom;
   Institute of Rheumatology, Prague
      2008   Phase 3   NCT00651040   Czech Republic;
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom;
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Ravulizumab
   Alexion Pharmaceuticals
      2021   Phase 2/Phase 3   NCT04999020   France;Germany;Italy;Korea, Republic of;Spain;United States;
Resunab, ajulemic acid, anabasum
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-SE   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-DE   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Serbia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003273-10-BG   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Rituximab
   Karolinska University Hospital
      2007   -   EUCTR2006-000078-65-SE   Czech Republic;Sweden;United Kingdom;
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
   University of Pittsburgh
      2006   Phase 2   NCT00106184   Canada;Czech Republic;Sweden;United Kingdom;United States;
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan;
RoActemra 162 mg soluzione iniettabile in siringa preriempita
   Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
      2018   Phase 2   EUCTR2018-000391-15-IT   Italy;
S78989
   Institut de Recherches Internationales Servier (IRIS)
      2014   -   EUCTR2012-005772-34-GR   Australia;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2014   -   EUCTR2012-005772-34-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2012-005772-34-IT   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2012-005772-34-CZ   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-SE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-HU   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-DE   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Laboratorios Servier S.L
      2013   -   EUCTR2012-005772-34-ES   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
   Servier Research and Development Ltd.
      2014   Phase 2   EUCTR2012-005772-34-GB   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
SODIUM THIOSULFATE PENTAHYDRATE
   CHU de LIMOGES
      2019   Phase 2   EUCTR2018-001978-22-FR   France;
STS
   University Hospital, Limoges
      2020   Phase 2   NCT03582800   France;
Siponimid
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
Siponimod
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-001799-39-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Japan;Poland;Taiwan;United States;
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States;
      2014   -   EUCTR2013-001799-39-PL   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States;
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States;
Siponimod 0.25 mg tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States;
Siponimod 0.5 mg tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States;
Siponimod 1 mg tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States;
Siponimod 2 mg Tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States;
Sodium Thiosulfate
   National Institute of Environmental Health Sciences (NIEHS)
      2017   Phase 2/Phase 3   NCT03267277   United States;
Sodium thiosulfate
   Alison Ehrlich
      2012   Phase 2   NCT01572844   United States;
Steroids
   RenJi Hospital
      2017   Phase 2   NCT03192657   China;
Tacrolimus
   Astellas Pharma Inc
      2014   -   NCT02159651   Japan;
   Department of Rheumatology and Immunology, Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR1900028143   China;
   Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032022   Japan;
   IMPPACT study central office
      2007   Phase 2-3   JPRN-JMA-IIA00012   Japan;
   Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032193   Japan;
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan;
   Tokyo Medical and Dental University
      2007   Phase 2/Phase 3   NCT00504348   Japan;
Tetanus protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
Tocilizumab
   Chester Oddis
      2014   Phase 2   NCT02043548   United States;
Tofacitinib
   Johns Hopkins University
      2017   Phase 1   NCT03002649   United States;
   Ren Ji Hospital South Campus, Shanghai Jiaotong University School of Medicine
      2017   -   ChiCTR1800016629   China;
   Zhongshan Hospital of Fudan University
      2020   -   ChiCTR2000036709   China;
Tofacitinib 5 MG [Xeljanz]
   Jing Liang
      2020   -   NCT04613219   China;
Treatment defined only by active substance
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom;
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-FR   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-ES   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-DE   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
Umbilical Cord Lining Stem Cells
   University of Florida
      2021   Early Phase 1   NCT04723303   United States;
Ustekinumab
   Janssen Pharmaceutical K.K.
      2019   Phase 3   NCT03981744   Japan;
      2019   Phase 3   JPRN-JapicCTI-194822   Japan;
VIB7734
   Viela Bio
      2018   Phase 1   NCT03817424   Poland;Spain;United States;
XOMA 052
   Institut de Recherches Internationales Servier (IRIS)
      2014   -   EUCTR2012-005772-34-GR   Australia;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2014   -   EUCTR2012-005772-34-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2012-005772-34-IT   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2012-005772-34-CZ   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-SE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-HU   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2013   -   EUCTR2012-005772-34-DE   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Laboratorios Servier S.L
      2013   -   EUCTR2012-005772-34-ES   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
   Servier Research and Development Ltd.
      2014   Phase 2   EUCTR2012-005772-34-GB   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Yellow Fever vaccine (17D)
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;
nifedipine cream
   Pontificia Universidad Catolica de Chile
      2016   Early Phase 1   NCT03027674   Chile;
sildenafil cream
   Pontificia Universidad Catolica de Chile
      2016   Early Phase 1   NCT03027674   Chile;
w/v isotonic sodium chloride solution
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States;